‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long - The Washington Post

Newly released clinical trial results show the oral drug daraxonrasib roughly doubled survival for patients with advanced pancreatic cancer, a major improvement for a disease with few effective treatments. The findings renew hope that targeting specific KRAS-driven mutations can deliver meaningful clinical benefit and may have implications for other tumors with the same mutations. Researchers caution that larger, confirmatory trials and broader validation are still needed before the pill becomes standard care.